tysabri
biogen netherlands b.v. - natalizumab - esclerosis múltiple - inmunosupresores selectivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
fingolimod mylan
mylan ireland limited - fingolimod clorhidrato de - la esclerosis múltiple remitente-recurrente - inmunosupresores - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 y 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
clariscan 0,5 mmol/ml solucion inyectable efg
ge healthcare bio-sciences, s.a.u. - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml inyectable 50 ml - gadoterico acido 0,5 mmol - Ácido gadotérico
clariscan 0,5 mmol/ml solucion inyectable en jeringa precargada efg
ge healthcare bio-sciences, s.a.u. - gadoterico acido - soluciÓn inyectable en jeringa precargada - 0,5 mmol/ml inyectable 20 ml - gadoterico acido 0,5 mmol - Ácido gadotérico
dotarem 0,5 mmol/ml solucion inyectable en jeringa precargada
guerbet - gadoterico acido - soluciÓn inyectable en jeringa precargada - 0,5 mmol/ml inyectable 20 ml - gadoterico acido 0,5 mmol - Ácido gadotérico
dotarem 0,5 mmol/ml solucion inyectable en vial
guerbet - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml - gadoterico acido 0,5 mmol - Ácido gadotérico
cyclolux 0,5 mmol/ml solucion inyectable efg
sanochemia pharmazeutika gmbh - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml inyectable 10 ml - gadoterico acido 0,5 mmol - Ácido gadotérico
cyclolux rep 0,5 mmol/ml solucion inyectable efg
sanochemia pharmazeutika gmbh - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml inyectable 10 ml - gadoterico acido 0,5 mmol - Ácido gadotérico
dotagraf 0,5 mmol/ml solucion inyectable unidosis efg
bayer hispania s.l. - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml - gadoterico acido 0,5 mmol - Ácido gadotérico